GALR2 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL2773511	0.59	14/20
SCHEMBL2773359	0.56	10/20
SCHEMBL2177922	0.51	8/20
SCHEMBL2772516	0.49	6/20
SCHEMBL3027057	0.36	6/20
SCHEMBL2409981	0.60	5/20
SCHEMBL2815529	0.48	5/20
SCHEMBL3019415	0.37	5/20
SCHEMBL3030544	0.35	5/20
SCHEMBL2175875	0.56	4/20
SCHEMBL2410626	0.50	4/20
SCHEMBL3018904	0.45	4/20
SCHEMBL1702461	0.44	4/20
SCHEMBL798400	0.41	4/20
SCHEMBL806710	0.41	4/20
SCHEMBL3029840	0.41	4/20
SCHEMBL1330337	0.39	4/20
SCHEMBL3027747	0.37	4/20
SCHEMBL3032808	0.37	4/20
SCHEMBL3023455	0.35	4/20

Clinical trials — most relevant to GALR2 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Investigating the Potential Role of Aerosolized Retinoic Acid, a Potent Vitamin A Metabolite for Treating COVID-19 Anosmia and Retinoic Acid Insufficiency .A Novel Approach for Regaining Sense of Smell.	PHASE4	UNKNOWN
Medication, Weight Gain and GI Hormones	PHASE4	COMPLETED
Effects of Genotype on Resting State Connectivity During Methamphetamine Administration	PHASE4	COMPLETED
A Study Of Galcanezumab In Participants With Episodic Cluster Headache	PHASE3	COMPLETED
Lemborexant Augmentation of Naltrexone for Alcohol Craving and Sleep	PHASE3	COMPLETED
The G Protein-Coupled Receptor Kinase Type 2 Inhibitor Paroxetine as Adjunctive Therapy to Improve Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus	PHASE3	UNKNOWN
A Study of LY2951742 (Galcanezumab) in Japanese Participants With Migraine	PHASE3	COMPLETED
A Phase 1/2 Study of Intravenous Gene Transfer With an AAV9 Vector Expressing Human Beta-galactosidase in Type I and Type II GM1 Gangliosidosis	PHASE1/PHASE2	RECRUITING
Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma	PHASE2	RECRUITING
A Series of Pilot Studies to Evaluate the haemoDynamic and mEtabolic Effects oF apelIn aNd rElaxin	PHASE2	UNKNOWN
68Ga-RM2 for PET/CT of Gastrin Releasing Peptide Receptor (GRPr) Expression in Prostate Cancer	PHASE2	COMPLETED
Studying the Influence of LEAP2 on Integrated Endocrine Control of Eating During Semaglutide Treatment	PHASE1/PHASE2	RECRUITING
Varenicline (Chantix™) for the Treatment of Alcohol Dependence	PHASE2	COMPLETED
A Study of LY2951742 (Galcanezumab) in Japanese Participants With Episodic Migraine	PHASE2	COMPLETED
Remote Ischaemic Conditioning in Endovascular Recanalization for Proximal Anterior Circulation Occlusion Study	PHASE1	UNKNOWN
Longitudinal Analysis of Amylin Levels in Migraine Patients Undergoing an Anti- CGRP/CGRPr Treatment	nan	NOT_YET_RECRUITING
Common Noradrenergic Mechanisms in Parkinson´s Disease and L-DOPA Induced Dyskinesia	nan	UNKNOWN
DOTATATE PETMRI AAA Study	nan	UNKNOWN
Auricular Vagus Stimulation in Obesity	nan	ACTIVE_NOT_RECRUITING
In Vitro Studies on Pharmacological Regulation and Genetic Risk Factors of Peripheral Human Nociceptors	nan	COMPLETED
BIOmarkers of MIGraine: a Proof of Concept Study Based on the Stratification of Responders to CGRP Monoclonal Antibodies	nan	COMPLETED
The Locus Coeruleus, Norepinephrine and Cognitive Aging	nan	ACTIVE_NOT_RECRUITING
Investigating Glucose Metabolism of LEAP2 With Total-body PET/CT	nan	ACTIVE_NOT_RECRUITING
Selective Activation of the Adrenomedullin Receptors in Migraine	nan	NOT_YET_RECRUITING
the Role of cArdiac Inflammation, endoThelial Dysfunction, and FIbrosis in fabrY Disease	nan	RECRUITING
Effect of Dietary Oils as G-protein-coupled Receptor Agonists on Glucose Tolerance	nan	UNKNOWN
Krabbe Disease Global Patient Registry	nan	RECRUITING
Effects of Probiotics on Gut Microbiota, Endocannabinoid and Immune Activation and Symptoms of Fatigue in Dancers	nan	COMPLETED
Brain Receptors in Sympathetic Nervous System Regulation	nan	COMPLETED
Potential Osteocatabolic Effect Caused by Anti-CGRP mAbs in Migraine Patients Treated With Anti-CGRP mAbs - an Observational Pilot Project With Prospectively Collected Health Related Data	nan	ACTIVE_NOT_RECRUITING

Related proteins — ESM-2 sequence neighbours (a GALR2 binder may also engage these)

Protein	Name	Similarity
O08726	—	1.000	O08726 →
O88854	—	0.998	O88854 →
O88626	—	0.988	O88626 →
Q924U1	—	0.987	Q924U1 →
HTR6	5-hydroxytryptamine receptor 6	0.986	landscape →
Q9XT58	—	0.983	Q9XT58 →
P30729	—	0.983	P30729 →
Q28524	—	0.983	Q28524 →
Q91V45	—	0.981	Q91V45 →
P51436	—	0.981	P51436 →
Q60483	—	0.981	Q60483 →
P30935	—	0.981	P30935 →
O88853	—	0.980	O88853 →
O02662	—	0.980	O02662 →
ADRB3	Beta-3 adrenergic receptor	0.980	landscape →
Q9TST4	—	0.979	Q9TST4 →
Q9R1C8	—	0.979	Q9R1C8 →
NMUR1	Neuromedin-U receptor 1	0.979	landscape →
Q8MJV2	—	0.977	Q8MJV2 →
P31388	—	0.977	P31388 →
Q5IS65	—	0.977	Q5IS65 →
Q95252	—	0.977	Q95252 →
Q63384	—	0.977	Q63384 →
NTSR2	Neurotensin receptor type 2	0.976	landscape →
Q9XT57	—	0.976	Q9XT57 →
KISS1R	KiSS-1 receptor	0.976	landscape →
Q6TLJ0	—	0.976	Q6TLJ0 →
P26255	—	0.976	P26255 →
RXFP4	Relaxin-3 receptor 2	0.976	landscape →
Q96P69	—	0.976	Q96P69 →